12858 Federal Register / Vol. 77, No. 42 / Friday, March 2, 2012 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel NIDA– 

K Special Emphasis Panel (SEP). 

Date: March 6, 2012. 

Time: 4:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Nadine Rogers, Ph.D., 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Blvd., Room 4229, MSC 9550, Bethesda, MD 

20892–9550, 301–402–2105, 

rogersn2@nida.nih.gov 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Collaborative Clinical Trials in Drug Abuse. 

Date: March 13, 2012. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Blvd., Room 4238, MSC 9550, Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Multisite Medications Development for 

SUDs. 

Date: March 15, 2012. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Blvd., Room 4238, MSC 9550, Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 2012 

Translational Avant Garde Review (DP1). 

Date: March 27, 2012. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn, 7301 Waverly 

Street, Bethesda, MD 20814. 

Contact Person: Scott A. Chen, Ph.D., 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4234, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–443–9511, 

chensc@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, DIDARP 

Review. 

Date: March 30, 2012. 

Time: 12 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Nadine Rogers, Ph.D., 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Blvd., Room 4229, MSC 9550, Bethesda, MD 

20892–9550, 301–402–2105, 

rogersn2@nida.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: February 24, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–5039 Filed 3–1–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center For Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Cell Biology. 

Date: March 21–22, 2012. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Wallace Ip, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5128, 

MSC 7840, Bethesda, MD 20892, 301–435– 

1191, ipws@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RFA Panel: 

CounterAct U54 Cooperative Agreements. 

Date: March 22, 2012. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco Alexandria, 480 King 

Street, Alexandria, VA 22314. 

Contact Person: Jonathan K Ivins, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040A, 

MSC 7806, Bethesda, MD 20892, (301) 594– 

1245, ivinsj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Fellowship: 

Oncological Sciences. 

Date: March 22–27, 2012. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Ross D Shonat, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5156, 

MSC 7849, Bethesda, MD 20892, 301–435– 

2786, shonatr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RFA Panel: 

CounterAct U01 Cooperative Agreements. 

Date: March 23, 2012. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco Alexandria, 480 King 

Street, Alexandria, VA 22314. 

Contact Person: Jonathan K Ivins, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040A, 

MSC 7806, Bethesda, MD 20892, (301) 594– 

1245, ivinsj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RFA MH12– 

080: Advancing HIV Prevention through 

Transformative Behavioral and Social 

Science Research. 

Date: March 23, 2012. 


tkelley on DSK3SPTVN1PROD with NOTICES